Fundraising Fox

OyaGen

Rochester, US · Delaware corporation

OyaGen is a preclinical drug discovery and development company that identifies and optimizes lead compounds as investigational new drugs for infectious diseases and cancer, then licenses or partners them with industry leaders for clinical development. It also offers fee-for-service assay development and high throughput screening to academic and industry partners.

BiotechDeep TechHealthtech

Founders & leadership

HC
Harold C. SmithFounder
RP
Ryan P. BennettCSO & Laboratory Director
RM
Richard McCloskeyNamed on SEC filing
TF
Thomas FitzgeraldChief Operations Officer
RO
Richard OgdenNamed on SEC filing
RM
Roscoe MooreNamed on SEC filing
KP
Kevin PhelpsChief Financial Officer & Treasurer
JC
Jose CoronasNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$345K disclosed across 1 round · 2017

▶$345KraisedDec 2017 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan BennettExecutive Officer
  • Richard McCloskeyDirector
  • Thomas FitzgeraldExecutive Officer, Promoter
  • Richard OgdenDirector
  • Harold SmithExecutive Officer, Director, Promoter
  • Roscoe MooreDirector
  • Kevin PhelpsExecutive Officer, Director
  • Jose CoronasDirector
Offering amount
$700K
Amount sold
$345K
Minimum investment
$25K
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Exagen14 shared keywordsExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
Nivagen10 shared keywordsNivagen provides drug product development services, guiding pharmaceutical companies through the full lifecycle from concept to commercialization, including traditional NDAs, 505(b)(2)s, and complex generics. The company serves pharmaceutical and biotech firms seeking to bring innovative drug products to market with intellectual property protection and accelerated timelines.
Ideagen8 shared keywordsIdeagen provides compliance and risk management software for regulated industries including aviation, life sciences, and food. The platform helps organizations in high-compliance sectors manage processes, people, and product safety.
Labcyte6 shared keywords

Companies competing with OyaGen for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$299K
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$572.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$600K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does OyaGen do?
OyaGen is a preclinical drug discovery and development company that identifies and optimizes lead compounds as investigational new drugs for infectious diseases and cancer, then licenses or partners them with industry leaders for clinical development. It also offers fee-for-service assay development and high throughput screening to academic and industry partners.
Who founded OyaGen?
OyaGen was founded by Harold C. Smith.
How much funding has OyaGen raised?
OyaGen has disclosed $345K raised across 1 round.
Where is OyaGen headquartered?
OyaGen is headquartered in Rochester, US.